Clinicopathologic Evaluation of Amyloid Clearance in Alzheimer Disease.
A man in his 50s with mild cognitive impairment and the Alzheimer disease risk-associated p.R47H TREM2 variant received 30 doses of aducanumab (cumulative dose 280 mg/kg) over 4.5 years in a clinical trial.
Clinical pearl
In this case, downstream tau pathology and MRI-measured atrophy differed by regional residual amyloid burden; amyloid clearance was not uniform across cortical regions.